TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Kymera Therapeutics
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

Kymera Therapeutics announced its 2026 clinical and preclinical milestones, including ongoing Phase 2b trials for KT-621 in atopic dermatitis and asthma with data expected in 2027, initiation of Phase 1 testing for KT-579 in Q1 2026, and advancement of at least one new development candidate toward IND. The company maintains $1.6 billion in cash with runway into 2029.

Insights
TpA   positive

Recognized in multiple award categories like Business Services, Cloud Networking, and Network Security, demonstrating broad technological capabilities


KYMR   positive

Company announced strong 2026 objectives with multiple clinical milestones, positive Phase 1b data for KT-621 showing efficacy comparable to dupilumab, FDA Fast Track designation, robust cash position of $1.6 billion with runway into 2029, and expansion of pipeline with new development candidates. Successful execution of strategy and clinical progress support positive outlook.